Abstract:The absence of stimulator of interferon genes (STING) in 129.B6. Fcgr2b -deficient mice rescue lupus phenotypes. The administration of a STING inhibitor (ISD017) into the young 129.B6. Fcgr2b -deficient mice prevents lupus nephritis development. This study mainly aimed to evaluate the effects of STING inhibition (ISD107) on established SLE in mice to prove that ISD017 could be a good therapeutic drug to reverse the already set-up autoimmunity and kidney impairment. Twenty-four-week-old Fcgr2b -deficient mice were treated with cyclophosphamide (25 mg/kg, intraperitoneal, once per week), ISD017 (10 mg/kg, intraperitoneal, three times per week), or control vehicle for 8 weeks, and were analyzed for phenotypes. Both ISD017 and cyclophosphamide treatment increased long-term survival and reduced the severity of glomerulonephritis in Fcgr2b -deficient mice. While cyclophosphamide reduced activated B cells (B220 + GL-7 + ), ISD017 decreased activated T cells (CD4 + CD69 + ) and neutrophils (Ly6c + Ly6g + ) in Fcgr2b -deficient mice. In addition, ISD017 reduced IL-1β and interferon-inducible genes. In summary, ISD017 treatment in symptomatic 129.B6. Fcgr2b -deficient mice reduced the severity of glomerulonephritis and increased long-term survival. ISD017 worked comparably to cyclophosphamide for treating lupus nephritis in 129.B6. Fcgr2b -deficient mice. ISD017 reduced activated T cells and neutrophils, while cyclophosphamide targeted activated B cells. These results suggested that STING inhibitors can potentially be a new therapeutic drug for treating lupus.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the effect of STING inhibitor (ISD017) on established systemic lupus erythematosus (SLE) and its nephritis symptoms. Specifically, the main objective of the study was to verify whether ISD017 can be an effective drug for treating established autoimmunity and kidney damage. To achieve this goal, the researchers used a 129.B6.Fcgr2b - deficient mouse model showing high levels of autoantibodies and proteinuria, and compared the effect of ISD017 with that of cyclophosphamide, a standard immunosuppressive treatment drug. ### Research Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by continuous immune activation leading to loss of self - tolerance and production of antibodies against nuclear antigens. Increased activity of type I interferon (IFN - type I) or abnormal signal transduction is considered one of the important pathogenic mechanisms of SLE. Deficiency of the Fcgr2b gene can exacerbate this pathological process, resulting in SLE - like symptoms in mice at 6 - 8 months. Therefore, Fcgr2b - deficient mice were selected as research objects to explore the role of the STING signaling pathway in SLE and potential therapeutic targets. ### Research Methods The researchers selected 24 - week - old Fcgr2b - deficient mice and gave them the following three treatments respectively: - Cyclophosphamide (25 mg/kg, intraperitoneal injection, once a week) - ISD017 (10 mg/kg, intraperitoneal injection, three times a week) - Control solvent (PBS) The treatment period was 8 weeks, during which the changes in the survival rate, nephritis severity and other relevant indicators of the mice were monitored. ### Main Findings 1. **Improved survival rate**: Both ISD017 and cyclophosphamide significantly improved the long - term survival rate of Fcgr2b - deficient mice. 2. **Reduced nephritis severity**: Both drugs reduced the severity of glomerulonephritis, but only cyclophosphamide decreased the urine protein/creatinine ratio. 3. **Cellular effects**: Cyclophosphamide mainly reduced activated B cells (B220+GL - 7+), while ISD017 reduced activated T cells (CD4+CD69+) and neutrophils (Ly6c+Ly6g+). 4. **Reduction of inflammatory factors**: ISD017 also reduced the expression of IL - 1β and interferon - inducible genes. ### Conclusion These results indicate that the STING inhibitor ISD017 can effectively alleviate established SLE and nephritis symptoms, and its effect is comparable to that of cyclophosphamide, with different mechanisms of action. This suggests that STING inhibitors may become a new therapy for SLE.

The STING inhibitor (ISD-017) reduces glomerulonephritis in 129.B6.Fcgr2b-deficient mice

STING Mediates Lupus via the Activation of Conventional Dendritic Cell Maturation and Plasmacytoid Dendritic Cell Differentiation

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

Elucidating the function of STING in systemic lupus erythematosus through the STING Goldenticket mouse mutant

A clinically-relevant STING agonist restrains human TH17 cell inflammatory profile

STING upregulation mediates ferroptosis and inflammatory response in lupus nephritis by upregulating TBK1 and activating NF-κB signal pathway

AB0045 MESENCHYMAL STEM CELLS INHIBIT THE ACTIVATED COMPLEMENT C5 BY CLUSTERIN IN LUPUS NEPHRITIS

Suppression of systemic autoimmunity by the innate immune adaptor STING

Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32)

C-176 inhibits macrophage polarization towards M1-subtype and ameliorates LPS induced acute kidney injury

Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor

Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice

Decrease of Functional Activated T and B Cells and Treatment of Glomerulonephitis in Lupus-Prone Mice Using a Natural Flavonoid Astilbin.

Gelsevirine is a novel STING-specific inhibitor and mitigates STING-related inflammation in sepsis

STING inhibitor ameliorates LPS-induced ALI by preventing vascular endothelial cells-mediated immune cells chemotaxis and adhesion

The protective effect of H151, a novel STING inhibitor, in renal ischemia-reperfusion-induced acute kidney injury

The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus.

Treatment with a CD40 Antagonist Antibody Reverses Severe Proteinuria and Loss of Saliva Production and Restores Glomerular Morphology in Murine Systemic Lupus Erythematosus

IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent

TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation

Disulfiram ameliorates STING/MITA-dependent inflammation and autoimmunity by targeting RNF115